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INTRODUCTION
Thalassemias are the most common mo-
nogenic diseases and are characterized by hy-
pochromic and microcytic anemia, which re-
sults from the absence (β0) or reduction (β+)
of the synthesis of β-globin chains. The main
pathological mechanism of this disorder is
the excess of a chains that precipitate blood
cell precursors, thereby inducing their pre-
mature destruction and making them inca-
pable of effective erythropoiesis. Three main
factors are responsible for the clinical mani-
festations of thalassemia intermedia: ineffec-
tive erythropoiesis, chronic anemia, and iron
overload. The severity of these factors de-
pends on the underlying molecular defects
that determine the relative excess of α-globin
chains. This is an extremely heterogeneous
disorder and more than 180 mutations have
been described around the world, causing
different degrees of illness.1
In the homozygous state, thalassemias are
generally classified clinically as either transfu-
sion-dependent, denominated Cooley anemia
or thalassemia major, or not requiring regular
transfusions, presenting a benign clinical course
and denominated thalassemia intermedia.
The aim of this study was to detect muta-
tions in the β-globin genes of a 72-year- old
Brazilian male patient of Italian descent with
thalassemia intermedia.
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METHODS
DNA was extracted and purified by means
of K proteinase, phenol and chloroform, as
previously described.2 The DNA amplification
method was followed, using 5 µl 10X Buffer
(200 mM Tris-HCl, pH 8.4; 500 mM KCl;
Gibco BRL Life Technologies); 5 µl 1 mM
dinucleotide triphosphotide (dNTP); 3 µl 50
mM magnesium chloride (MgCl
2
); 0.5 µl, 0.5
units Taq polymerase; 1 µl oligonucleotide
primer 20 mol/µl; and 5 µl patient DNA. Five
pairs of primers were used (P1: TCC TAA
GCC AGT G, P5: TCA TTC GTC TGT
TTC CCA TTC, B1: TTT GCT TCT GAC
ACA ACT GT, 109: CCC TTC CTA TGC
ATG AAG TTA ACC AT, 58: AAT CCA
GCT ACC ATT CTG C, P7: GAC CTC
CCA CAT TCC CTT TTT, Prom3: GGT
GTC TGT TTG AGG TTG, Prom5: CCA
AAT AAG GAG AAG ATA TG, Exon3: CTG
TGG GAG GAA GAT AAG AGG, Exon5:
GTG AGT CTA TGG GAC CCT TG).
The cycle began with 94 ºC for 2 min-
utes, followed by 30 cycles of 94 ºC for 30
seconds, annealing temperature variations
from 53 to 64 ºC for 45 seconds, 72 ºC for 1
minute and last extension reaction at 72 ºC
for 7 minutes. The PCR products were dis-
played via agarose gel electrophoresis 1% with
ethidium bromide.
The fractions were purified using the
Gibco Concert kit. The sequence reactions
were performed using 3 µl of DNA, 4 µl of
Big Dye, 6 µl of save money, 1.3 µl of primer
5 mol/µl, and 5.7 µl of water. The PCR cy-
cle began with 96 ºC for 90 seconds, 25 cy-
cles of 96 ºC for 12 seconds, 50 ºC for 6
seconds and 60 ºC for 4 minutes. The PCR
products were sequenced using the ABI
PRISM 3700. The chromatograms were
analyzed via the software programs PHRED,3
PHRAP4 and CONSED.5
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CONTEXT: We verified molecular alterations in a 72-
year-old Brazilian male patient with a clinical
course of homozygous β-thalassemia intermedia,
who had undergone splenectomy and was sur-
viving without regular blood transfusions. The
blood cell count revealed microcytic and hy-
pochromic anemia (hemoglobin = 6.5 g/dl, mean
cell volume = 74 fl, mean cell hemoglobin = 24
pg) and hemoglobin electrophoresis showed fe-
tal hemoglobin = 1.3%, hemoglobin A2 = 6.78%
and hemoglobin A = 79.4%.
OBJECTIVE: To identify mutations in a patient with the
symptoms of β-thalassemia intermedia.
DESIGN: Molecular inquiry into the mutations possibly
responsible for the clinical picture described.
SETTING: The structural molecular biology and genetic
engineering center of the Universidade Estadual
de Campinas, Campinas, Brazil.
PROCEDURES: DNA extraction was performed on the
patient’s blood samples. The polymerase chain re-
action (PCR) was done using five specific primers
that amplified exons and the promoter region of
the β globin gene. The samples were sequenced
and then analyzed via computer programs.
RESULTS: Two mutations that cause the disease were
found: -101 (C > T) and codon 39 (C > T).
CONCLUSIONS: This case represents the first descrip-
tion of –101 (C > T) mutation in a Brazilian popu-
lation and it is associated with a benign clinical
course.
KEY WORDS: Beta thalassemia. Mutations. Beta
globin.
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PATIENT AND RESULTS
The patient was a 72-year-old male with a
clinical course characteristic of thalassemia
intermedia, who did not require regular trans-
fusions. He did not present the  classical features
of severe clinical complications that are seen in
thalassemia major. He presented mild anemia
and had undergone splenectomy at the age of
30 years. The hematological data showed mi-
crocytic and hypochromic anemia (hemoglobin
= 7.9 g/dl, mean cell volume = 76 fl, mean cell
hemoglobin = 26 pg) and the hemoglobin elec-
trophoresis indicated fetal hemoglobin = 14.2%,
hemoglobin A
2 
= 6.2% and hemoglobin A =
79.6%. One mutation was identified at the po-
sition – 101 (C > T) in the β-globin gene pro-
moter in one allele and another mutation in
codon 39 (C > T) in the other allele.
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DISCUSSION
 The promoter mutation was classified as
extremely mild and an association was made
with the heterozygosis of the silent carrier
phenotype, which is characterized by little or
no hypochromia and microcytosis of the red
blood cells. This mutation was first described
in Italians. The other mutation, resulting from
a stop codon, is also common in the Mediter-
ranean population and is the most frequently-
found mutation in Brazil.
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CONCLUSION
This study provides the first description of
the – 101 (C > T) mutation in Brazil and em-
phasizes the clinical variability of homozygosis
for beta thalassemia in the Brazilian population.
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CONTEXTO: Neste trabalho foi estudada a
alteração molecular em um paciente brasileiro
de 72 anos com talassemia β homozigótica
com evolução clínica intermediária, esple-
nectomizado e necessitando de transfusões
ocasionais. Os dados hematológicos mostra-
vam anemia microcítica e hipocrômica
(Hemoglobina = 7,9 g/dl, Volume Corpus-
cular Médio =  76fl, Hemoblobina Corpus-
cular Média = 26 pg) e a eletroforese de
hemoglobina revelou Hemoglobina Fetal =
14,2%, Hemoglobina A
2 
= 6,2% e Hemo-
globina A = 79,4%.
OBJETIVO: Identificar as duas mutações en-
volvendo um paciente com sintomas de
talassemia beta intermediária.
TIPO DE ESTUDO: Investigação molecular das
possíveis mutações responsáveis pelo quadro
clínico descrito.
LOCAL: Centro de Biologia Molecular e Enge-
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PROCEDIMENTOS: Após a extração de DNA
do sangue deste paciente, foi feita  reação de
polimerase em cadeia (polymerase chain reac-
tion, PCR) utilizando cinco pares de primers
que amplificaram éxons e a região promotora
do gene da globina β. O produto da am-
plificação foi seqüenciado e os croma-
togramas, analisados por programas de
computador (Phred, Phrap e Consed).
RESULTADOS: Foram encontradas duas mu-
tações responsáveis pela doença;-101 (C > T)
e códon 39 (C > T).
CONCLUSÕES: Este caso representa a primeira
descrição da mutação –101 (C > T) na
população brasileira e está associado a
evolução clínica benigna.
PALAVRAS-CHAVE: β-talassemia. Mutações.
Globina β.
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